Manoj Kumar Sarangi

Manoj Kumar Sarangi

Auto-generated profile, based on publicly available information

Manoj Kumar Sarangi

Department of Pharmaceutics, Amity Institute of Pharmacy Amity University Uttar Pradesh Lucknow India

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2020 in International Journal of Polymeric Materials and Polymeric Biomaterials
Verified
Journal Article
Closed access
MSManoj Kumar Sarangi
Manoj Kumar Sarangi
MRM. E. Bhanoji Rao
M. E. Bhanoji Rao
VPVersha Parcha
Versha Parcha
The colon targeted drug delivery has a number of important implications in the field of pharmacotherapy. Oral colon targeted drug delivery systems have recently gained importance for delivering a variety of therapeutic agents for both local and systemic administration. Targeting of drugs to the colon via oral administration to protect the drug from degradation or release in the stomach and small intestine. It also ensures abrupt or controlled release of the drug in the proximal colon. Various drug delivery systems have been designed that deliver the drug quantitatively to the colon and then trigger the release of the drug. This review will cover different types of polymers which can be used in the formulation of colon targeted drug delivery systems.

12 December 2023 in Chinese Chemical Letters
Verified
Journal Article
Closed access
MSManoj Kumar Sarangi
Manoj Kumar Sarangi
LPL․d Patel
L․d Patel
GRGoutam Rath
Goutam Rath
SNSitansu Sekhar Nanda
Sitansu Sekhar Nanda
DYDong Kee Yi
Dong Kee Yi

1 February 2021 in Biological Procedures Online
Verified
Journal Article
Open access
PDF file
JCJyoti Choudhary
Jyoti Choudhary
Shrivardhan DheemanShrivardhan Dheeman
Shrivardhan Dheeman
VKVipin Kumar
Vipin Kumar
PKPrashant Katiyar
Prashant Katiyar
SKSantosh Kumar Karn
Santosh Kumar Karn
NBNitin baliyan
Nitin baliyan
COVID-19, a pandemic of the 21st century caused by novel coronavirus SARS-CoV-2 was originated from China and shallowed world economy and human resource. The medical cures via herbal treatments, antiviral drugs, and vaccines still in progress, and studying rigorously. SARS-CoV-2 is more virulent than its ancestors due to evolution in the spike protein(s), mediates viral attachment to the host’s membranes. The SARS-CoV-2 receptor-binding spike domain associates itself with human angiotensin-converting enzyme 2 (ACE-2) receptors. It causes respiratory ailments with irregularities in the hepatic, nervous, and gastrointestinal systems, as reported in humans suffering from COVID-19 and reviewed in the present article. There are several approaches, have been put forward by many countries under the world health organization (WHO) recommendations and some trial drugs were introduced for possible treatment of COVID-19, such as Lopinavir or Ritonavir, Arbidol, Chloroquine (CQ), Hydroxychloroquine (HCQ) and most important Remdesivir including other like Tocilizumab, Oritavancin, Chlorpromazine, Azithromycin, Baricitinib, etc. RT-PCR is the only and early detection test available besides the rapid test kit (serodiagnosis) used by a few countries due to unreasonable causes. Development of vaccine by several leader of pharmaceutical groups still under trial or waiting for approval for mass inoculation. Management strategies have been evolved by the recommendations of WHO, specifically important to control COVID-19 situations, in the pandemic era. This review will provide a comprehensive collection of studies to support future research and enhancement in our wisdom to combat COVID-19 pandemic and to serve humanity.

13 July 2021 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
MSManoj Kumar Sarangi
Manoj Kumar Sarangi
SPSasmita Padhi
Sasmita Padhi
Shrivardhan DheemanShrivardhan Dheeman
Shrivardhan Dheeman
SKSantosh Kumar Karn
Santosh Kumar Karn
LPL. D. Patel
L. D. Patel
Sitansu Sekhar NandaSitansu Sekhar Nanda
Sitansu Sekhar Nanda
Coronavirus disease (COVID-19) was first reported in Wuhan, China, in late December 2019 and subsequently, declared a pandemic. As of 3 June 2021, 172,493,290 individuals have acquired COVID-19 and...

28 December 2022 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
SRSudhanshu Ranjan Rout
Sudhanshu Ranjan Rout
BKBiswakanth Kar
Biswakanth Kar
DPDeepak Pradhan
Deepak Pradhan
PBPrativa Biswasroy
Prativa Biswasroy
JHJitu Haldar
Jitu Haldar
GRGoutam Rath
Goutam Rath
Oral mucositis is a serious issue in patients receiving oncological therapies. Mucosal protectants considered to be one of the preferred choices used in the management of mucositis. However, the protective efficacy of currently available mucosal protectants has been significantly compromised due to poor retention, lack of lubrication, poor biodegradability, and inability to manage secondary complications. Chitosan is a promising material for mucosal applications due to its beneficial biomedical properties. Chitosan is also anti-inflammatory, anti-microbial, and capable of scavenging free radicals, makes it a good candidate for the treatment of oral mucositis. Additionally, chitosan's amino polysaccharide skeleton permits a number of chemical alterations with better bioactive performance. This article provides a summary of key biological properties of chitosan and its derivatives that are useful for treating oral mucositis. Current literature evidence shows that Chitosan has superior mucosal protective properties when utilised alone or as delivery systems for co-encapsulated drugs. Graphical Abstract

19 April 2024 in Macromolecular Bioscience
Verified
Journal Article
Closed access
RSRishika Singhal
Rishika Singhal
MSManoj Kumar Sarangi
Manoj Kumar Sarangi
GRGoutam Rath
Goutam Rath